Lp(a)'s Odyssey: Should We Measure Lp(a) Post-ACS and What Should We Do With the Results?

J Am Coll Cardiol. 2020 Jan 21;75(2):145-147. doi: 10.1016/j.jacc.2019.11.016.
No abstract available

Keywords: acute coronary syndromes; alirocumab; low-density lipoprotein cholesterol; major adverse cardiovascular events; proprotein convertase subtilisin/kexin type 9 inhibition.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Acute Coronary Syndrome*
  • Antibodies, Monoclonal, Humanized
  • Cardiovascular Diseases*
  • Humans
  • Lipoprotein(a)
  • Proprotein Convertase 9
  • Risk Factors

Substances

  • Antibodies, Monoclonal, Humanized
  • Lipoprotein(a)
  • Proprotein Convertase 9
  • alirocumab